OS Therapies Terminates Equity Line of Credit
OS Therapies (NYSE American: OSTX) has announced the termination of its Equity Purchase Agreement (ELOC) with Square Gate Capital Master Fund, LLC - Series 3, effective August 26, 2025. The company recently secured $4.2 million in gross proceeds through a warrant exercise inducement and exchange offering, providing operational funding through mid-2026.
The company has completed the treatment phases of two clinical trials: the Phase 2b OST-HER2 trial in osteosarcoma and the Phase 1b OST-504 trial in prostate cancer. With reduced projected monthly expenses in H2 2025, OS Therapies will focus on pursuing approval for OST-HER2 while evaluating development options for OST-504.
OS Therapies (NYSE American: OSTX) ha comunicato la risoluzione del suo Equity Purchase Agreement (ELOC) con Square Gate Capital Master Fund, LLC - Series 3, con effetto dal 26 agosto 2025. La società ha recentemente ottenuto 4,2 milioni di dollari di proventi lordi tramite un incentivo all'esercizio di warrant e un'offerta di scambio, garantendo finanziamenti operativi fino alla metà del 2026.
OS Therapies ha completato le fasi di trattamento di due studi clinici: il Phase 2b OST-HER2 nell'osteosarcoma e il Phase 1b OST-504 nel carcinoma prostatico. Con la riduzione delle spese mensili previste nella seconda metà del 2025, la società concentrerà gli sforzi sull'ottenimento dell'approvazione per OST-HER2 e valuterà opzioni di sviluppo per OST-504.
OS Therapies (NYSE American: OSTX) ha anunciado la terminación de su Equity Purchase Agreement (ELOC) con Square Gate Capital Master Fund, LLC - Series 3, con efecto a partir del 26 de agosto de 2025. La compañía obtuvo recientemente 4,2 millones de dólares en ingresos brutos mediante un incentivo para el ejercicio de warrants y una oferta de intercambio, lo que le proporciona financiación operativa hasta mediados de 2026.
La empresa ha completado las fases de tratamiento de dos ensayos clínicos: el Phase 2b OST-HER2 en osteosarcoma y el Phase 1b OST-504 en cáncer de próstata. Con unos gastos mensuales proyectados menores en la segunda mitad de 2025, OS Therapies se centrará en buscar la aprobación de OST-HER2 y evaluará opciones de desarrollo para OST-504.
OS Therapies (NYSE American: OSTX)는 2025년 8월 26일부로 Square Gate Capital Master Fund, LLC - Series 3와의 Equity Purchase Agreement(ELOC)를 종료했다고 발표했습니다. 회사는 최근 워런트 행사 유도 및 교환 공모를 통해 총 420만 달러의 자금을 확보해 2026년 중반까지 운영 자금을 확보했습니다.
회사는 두 건의 임상시험 치료 단계를 완료했습니다: 골육종 대상의 Phase 2b OST-HER2와 전립선암 대상의 Phase 1b OST-504. 2025년 하반기에 예상 월간 비용이 감소함에 따라, OS Therapies는 OST-HER2의 승인 추진에 주력하고 OST-504의 개발 옵션을 검토할 예정입니다.
OS Therapies (NYSE American: OSTX) a annoncé la résiliation de son Equity Purchase Agreement (ELOC) avec Square Gate Capital Master Fund, LLC - Series 3, à compter du 26 août 2025. La société a récemment obtenu 4,2 millions de dollars de produits bruts via une incitation à l'exercice de warrants et une offre d'échange, assurant un financement opérationnel jusqu'au milieu de 2026.
La société a achevé les phases de traitement de deux essais cliniques : le Phase 2b OST-HER2 dans l'ostéosarcome et le Phase 1b OST-504 dans le cancer de la prostate. Avec des dépenses mensuelles prévues en baisse au second semestre 2025, OS Therapies se concentrera sur l'obtention de l'approbation pour OST-HER2 et évaluera des options de développement pour OST-504.
OS Therapies (NYSE American: OSTX) hat die Beendigung seines Equity Purchase Agreement (ELOC) mit Square Gate Capital Master Fund, LLC - Series 3 zum 26. August 2025 bekannt gegeben. Das Unternehmen hat kürzlich 4,2 Millionen US-Dollar Bruttoerlös durch die Ausübung von Warrants und ein Umtauschangebot erhalten und damit die operative Finanzierung bis Mitte 2026 gesichert.
Das Unternehmen hat die Behandlungsphasen von zwei klinischen Studien abgeschlossen: die Phase 2b OST-HER2 bei Osteosarkom und die Phase 1b OST-504 beim Prostatakrebs. Bei verringerten prognostizierten Monatsausgaben in der zweiten Hälfte des Jahres 2025 wird sich OS Therapies auf die Zulassung von OST-HER2 konzentrieren und Entwicklungsoptionen für OST-504 prüfen.
- Secured $4.2 million in gross proceeds to fund operations through mid-2026
- Completed treatment phases for both Phase 2b OST-HER2 and Phase 1b OST-504 trials
- Reduced monthly burn rate expected for H2 2025
- Strong cash position eliminates need for ELOC facility
- Termination of ELOC reduces financial flexibility for future funding needs
New York, New York--(Newsfile Corp. - August 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it terminated its Equity Purchase Agreement (the "ELOC") with Square Gate Capital Master Fund, LLC — Series 3, effective August 26, 2025.
"The recent success of our warrant exercise inducement and exchange offering provided the Company with
Mr. Romness noted, "With the treatment phases of our Phase 2b OST-HER2 clinical trial in osteosarcoma and our Phase 1b OST-504 clinical trial in prostate cancer now complete, our projected monthly burn in the second half of 2025 is significantly less than it was in the first half of 2025. We intend to judiciously allocate our capital primarily to drive towards an approval for OST-HER2 in osteosarcoma while in parallel analyzing the data generated for OST-504 in prostate cancer to determine the next step in its product development life cycle."
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in "Risk Factors" in the Company's most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
OS Therapies Contact Information:
Investor Relations
Harrison Seidner, PhD
WaterSeid Partners
OSTX@waterseid.com
Public Relations
Stephanie Chen
Elev8 New Media
stephanie@elev8newmedia.com
https://x.com/OSTherapies
https://www.instagram.com/ostherapies/
https://www.facebook.com/OSTherapies/
https://www.linkedin.com/company/os-therapies/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263891
FAQ
Why did OS Therapies (OSTX) terminate its Equity Line of Credit in August 2025?
How long will OS Therapies' (OSTX) current funding last?
What clinical trials has OS Therapies (OSTX) completed in 2025?
What are OS Therapies' (OSTX) main priorities after terminating the ELOC?
How has OS Therapies' (OSTX) financial outlook changed for H2 2025?
